Our team focuses on the identification of new physiological and molecular pathways in lipoprotein metabolism and cardiovascular diseases. Among cardiovascular risk factors, LDL-cholesterol (LDL-C) plays a critical role in the development of atherosclerosis. The first goal of our team is therefore to improve deciphering of the hepatic and intestinal metabolism of LDL in order to identify new pathways and ultimately new drug targets for hypercholesterolemia (RHU CHOPIN).
We also use seipin knockout mice as a unique model of congenital generalized lipodystrophy to decipher the molecular links between adipocyte dysfunction and cardiometabolic complications.

To assess these goals, we have built a multi-skilled team with a highly translational approach, highlighted by our contribution in the field of PCSK9, a master regulator of LDL-C homeostasis and a validated drug target for hypercholesterolemia.
We are notably working in close interaction with the CIC ‘Endocrinology & Nutrition’ (CHU NANTES, INSERM 1413; scientific coordinator: Bertrand Cariou; translational project manager: Matthieu Pichelin) to recruit patients and conduct both observational and interventional clinical studies.

We have also acquired a well-reputed expertise in the in vivo phenotyping of lipoprotein metabolism in mice, with a specific focus on intestinal lipoprotein metabolism. We are notably working on trans-intestinal cholesterol excretion or TICE (Cédric Le May).
In parallel we have developed innovative tools to address our scientific questions such as, for instance, urine sample-derived human induced pluripotent stem cells (UhiPSC) differentiated in hepatocytes (Karim Si-Tayeb) or an inducible seipin knock-down adipocyte cell line (Xavier Prieur).
PCSK9
LDL
seipin